Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
38
SXTC Quote, Financials, Valuation and Earnings
Last price:
$1.41
Seasonality move
:
24.22%
Day range:
$1.36 - $1.37
52-week range:
$0.95 - $7.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.53x
P/B ratio:
48.02x
Volume:
1.6K
Avg. volume:
218.5K
1-year change:
-64.78%
Market cap:
$157.8M
Revenue:
$1.7M
EPS (TTM):
-$16.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SXTC
China Sxt Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.92% | -46.43% | $49.49 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SXTC
China Sxt Pharmaceuticals, Inc.
|
$1.36 | -- | $157.8M | -- | $0.00 | 0% | 5.53x |
|
ADAG
Adagene, Inc.
|
$1.91 | $9.22 | $90.2M | -- | $0.00 | 0% | 861.40x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.86 | $4.00 | $17.6M | -- | $0.00 | 0% | 0.50x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.75 | -- | $5.7M | -- | $0.00 | 0% | 1.41x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$18.70 | $49.49 | $2.1B | -- | $0.00 | 0% | 4.54x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SXTC
China Sxt Pharmaceuticals, Inc.
|
14.76% | -0.199 | 64.71% | 1.51x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SXTC
China Sxt Pharmaceuticals, Inc.
|
-- | -- | -21.9% | -27.59% | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
China Sxt Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SXTC or ADAG?
Adagene, Inc. has a net margin of -- compared to China Sxt Pharmaceuticals, Inc.'s net margin of --. China Sxt Pharmaceuticals, Inc.'s return on equity of -27.59% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital SXTCChina Sxt Pharmaceuticals, Inc.-- -- $16.3M ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About SXTC or ADAG?
China Sxt Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 381.94%. Given that Adagene, Inc. has higher upside potential than China Sxt Pharmaceuticals, Inc., analysts believe Adagene, Inc. is more attractive than China Sxt Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTCChina Sxt Pharmaceuticals, Inc.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is SXTC or ADAG More Risky?
China Sxt Pharmaceuticals, Inc. has a beta of 1.447, which suggesting that the stock is 44.71% more volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SXTC or ADAG?
China Sxt Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Sxt Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTC or ADAG?
China Sxt Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Adagene, Inc. quarterly revenues of --. China Sxt Pharmaceuticals, Inc.'s net income of -- is lower than Adagene, Inc.'s net income of --. Notably, China Sxt Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Sxt Pharmaceuticals, Inc. is 5.53x versus 861.40x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTCChina Sxt Pharmaceuticals, Inc.5.53x -- -- -- ADAGAdagene, Inc.861.40x -- -- --
-
Which has Higher Returns SXTC or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to China Sxt Pharmaceuticals, Inc.'s net margin of -353.92%. China Sxt Pharmaceuticals, Inc.'s return on equity of -27.59% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital SXTCChina Sxt Pharmaceuticals, Inc.-- -- $16.3M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About SXTC or CASI?
China Sxt Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 366.8%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than China Sxt Pharmaceuticals, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than China Sxt Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTCChina Sxt Pharmaceuticals, Inc.0 0 0 CASICASI Pharmaceuticals, Inc.0 0 0 -
Is SXTC or CASI More Risky?
China Sxt Pharmaceuticals, Inc. has a beta of 1.447, which suggesting that the stock is 44.71% more volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock SXTC or CASI?
China Sxt Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Sxt Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTC or CASI?
China Sxt Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. China Sxt Pharmaceuticals, Inc.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, China Sxt Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Sxt Pharmaceuticals, Inc. is 5.53x versus 0.50x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTCChina Sxt Pharmaceuticals, Inc.5.53x -- -- -- CASICASI Pharmaceuticals, Inc.0.50x -- $3.1M -$10.9M
-
Which has Higher Returns SXTC or CPHI?
China Pharma Holdings, Inc. has a net margin of -- compared to China Sxt Pharmaceuticals, Inc.'s net margin of -86.16%. China Sxt Pharmaceuticals, Inc.'s return on equity of -27.59% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital SXTCChina Sxt Pharmaceuticals, Inc.-- -- $16.3M CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About SXTC or CPHI?
China Sxt Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that China Sxt Pharmaceuticals, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe China Sxt Pharmaceuticals, Inc. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTCChina Sxt Pharmaceuticals, Inc.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is SXTC or CPHI More Risky?
China Sxt Pharmaceuticals, Inc. has a beta of 1.447, which suggesting that the stock is 44.71% more volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock SXTC or CPHI?
China Sxt Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Sxt Pharmaceuticals, Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTC or CPHI?
China Sxt Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. China Sxt Pharmaceuticals, Inc.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, China Sxt Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Sxt Pharmaceuticals, Inc. is 5.53x versus 1.41x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTCChina Sxt Pharmaceuticals, Inc.5.53x -- -- -- CPHIChina Pharma Holdings, Inc.1.41x -- $756.2K -$651.5K
-
Which has Higher Returns SXTC or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to China Sxt Pharmaceuticals, Inc.'s net margin of --. China Sxt Pharmaceuticals, Inc.'s return on equity of -27.59% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital SXTCChina Sxt Pharmaceuticals, Inc.-- -- $16.3M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About SXTC or SVA?
China Sxt Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that China Sxt Pharmaceuticals, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe China Sxt Pharmaceuticals, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SXTCChina Sxt Pharmaceuticals, Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is SXTC or SVA More Risky?
China Sxt Pharmaceuticals, Inc. has a beta of 1.447, which suggesting that the stock is 44.71% more volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock SXTC or SVA?
China Sxt Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. China Sxt Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios SXTC or SVA?
China Sxt Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. China Sxt Pharmaceuticals, Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, China Sxt Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Sxt Pharmaceuticals, Inc. is 5.53x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTCChina Sxt Pharmaceuticals, Inc.5.53x -- -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns SXTC or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to China Sxt Pharmaceuticals, Inc.'s net margin of -30.98%. China Sxt Pharmaceuticals, Inc.'s return on equity of -27.59% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital SXTCChina Sxt Pharmaceuticals, Inc.-- -- $16.3M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About SXTC or ZLAB?
China Sxt Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.49 which suggests that it could grow by 164.64%. Given that Zai Lab Ltd. has higher upside potential than China Sxt Pharmaceuticals, Inc., analysts believe Zai Lab Ltd. is more attractive than China Sxt Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SXTCChina Sxt Pharmaceuticals, Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is SXTC or ZLAB More Risky?
China Sxt Pharmaceuticals, Inc. has a beta of 1.447, which suggesting that the stock is 44.71% more volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock SXTC or ZLAB?
China Sxt Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Sxt Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SXTC or ZLAB?
China Sxt Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. China Sxt Pharmaceuticals, Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, China Sxt Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Sxt Pharmaceuticals, Inc. is 5.53x versus 4.54x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SXTCChina Sxt Pharmaceuticals, Inc.5.53x -- -- -- ZLABZai Lab Ltd.4.54x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
50
PLAB alert for Dec 10
Photronics, Inc. [PLAB] is up 45.35% over the past day.
Buy
60
OLMA alert for Dec 10
Olema Pharmaceuticals, Inc. [OLMA] is up 15.35% over the past day.
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 3.07% over the past day.
